Andrey N. Makarenko

Learn More
A scheme of complex administration of drugs in the order neuroprotector + neuroactivator + neuroretarder for the treatment of neurodegenerative processes in the brain has been elaborated and tested on a model object representing neurodegenerative mutants of Drosophila melanogaster. The appearance of changes in the brain was delayed when drugs were used(More)
The effect of the new drug "cerebral" and its fractions 1-3 on the model of bilateral hemorrhagic stroke in white rats was studied with reference to the action of cebrolysin and cerebrolysate-M. With respect to the general functional state, behavioral activity restoration, and morphological data, the most pronounced antistroke action was observed for the(More)
Effects of the nootropic neuropeptide drugs cerebrolysin (Ebewe, Austria) and cortexin (Geterofarm, Russia) on the immunocompetent cells (T-lymphocytes of the MT-4 cell line and B-lymphocytes of the Raji cell line) were studied in vitro. The cell viability was evaluated using the MTT test by counting living and dead cells upon incubation under various(More)
A standardized experimental model of intracerebral hemorrhagic stroke in small laboratory animals is developed and advanced for chronic neurobiological studies of normal and pathological higher nervous activity as well as disorders developed after acute hemorrhages. A device is advanced which allows a researcher to destroy appropriate brain structures(More)
For the description of the Universe expansion, compatible with observational data, a model of Lovelock gravity with dilaton is investigated. D-dimensional space with 3and (D-4)-dimensional maximally symmetric subspaces is considered. Space without matter and space with perfect fluid are under test. In various forms of the theory (third order without dilaton(More)
A homogeneous low-molecular-weight fraction (MW, 350-500 Da) separated from a ready-to-use commercial form of the new neurotropic drug cerebral (for amino acid composition see Arkh. Psikh. 3(18), 138-143 (1998)) increases the survival of experimental rats upon experimental hemorrhagic stroke (HS). The distribution and accumulation of tritium-labeled(More)
The new drug cerebral, as well as its low-molecular-weight (LMW) fraction (MW, < or = 500 Da) separated from a ready-to-use commercial form of this new neutrotropic drug, increases the level of synthesis and secretion of the nerve growth factor (NGF) in rats under conditions of experimental hemorrhagic stroke (HS), while not influencing the NGF synthesis(More)
Active anti-stroke fraction of Cerebral preparation (extract of water-soluble molecules from brain tissue of animals with hemorrhagic stroke) decreased caspase-3 expression and improved survival of experimental animals in the acute period after hemorrhagic stroke.
Neuroimmunocorrection therapy with cerebrolysin has been used for the prophylaxis of clinical pneumonia development in the early stage of acute stroke in a group of 140 patients with heavy clinical course of acute ischemic stroke (AIS). All patients in the test and control groups received the basal anti-AIS therapy and antibacterial drugs (IV-generation(More)